Implications of fluorodeoxyglucose uptake in low-intermediate grade metastatic neuroendocrine tumors from peptide receptor radionuclide therapy outcome viewpoint: A semi-quantitative standardized uptake value-based analysis.

World J Nucl Med · 2019 · PMC6945359 · PMID 31933555

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients with high baseline tumor metabolism SUV max >10 (Group 3) showed a trend that subtly favored symptomatic progression with 33% patients showing symptomatic progression (PD).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.